top of page

Search

MUVON Minute: First manifesto for SUI policy reform signed

Muvon
Dec 12, 2023
0 min read

Recent Posts

Dr. Thomas Meier elected as new Chairman of the Board of Directors at MUVON Therapeutics’ Annual General Meeting 2025

Dr. Thomas Meier elected as new Chairman of the Board of Directors at MUVON Therapeutics’ Annual General Meeting 2025

MUVON Completes Patient Enrollment of Randomized Phase 2 Clinical Study Evaluating Muscle Precursor Cell (MPC)-based Therapy in Stress Urinary Incontinence and Expects Topline Data in Q3 2025

Zurich, Switzerland, April 16, 2025 – MUVON Therapeutics AG, an innovative clinical-stage biotechnology company, announces dosing of the...

MUVON Therapeutics Clears Phase 2 Interim Milestone and Will Participate in the 2025 J.P. Morgan Healthcare Conference

MUVON Therapeutics Clears Phase 2 Interim Milestone and Will Participate in the 2025 J.P. Morgan Healthcare Conference

Comentários

bottom of page